ALCARTIS

Land: Ierland

Taal: Engels

Bron: HPRA (Health Products Regulatory Authority)

Koop het nu

Download Productkenmerken (SPC)
02-10-2016

Werkstoffen:

ARIPIPRAZOLE

Beschikbaar vanaf:

EGIS Pharmaceuticals PLC

ATC-code:

N05AX12

INN (Algemene Internationale Benaming):

ARIPIPRAZOLE

Dosering:

10 Milligram

farmaceutische vorm:

Tablets

Prescription-type:

Product subject to prescription which may not be renewed (A)

Therapeutisch gebied:

aripiprazole

Autorisatie-status:

Not Marketed

Autorisatie datum:

2016-02-26

Productkenmerken

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Alcartis 10 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10 mg aripiprazole.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
White or almost white, round, convex tablets with stylized E and 562
code on one side and no engraving on the other
side. The diameter of the tablet is about 7 mm.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Alcartis is indicated for the treatment of schizophrenia in adults and
in adolescents aged 15 years and older.
Alcartis is indicated for the treatment of moderate to severe manic
episodes in Bipolar I Disorder and for the prevention
of a new manic episode in adults who experienced predominantly manic
episodes and whose manic episodes responded
to aripiprazole treatment (see section 5.1).
Alcartis is indicated for the treatment up to 12 weeks of moderate to
severe manic episodes in Bipolar I Disorder in
adolescents aged 13 years and older (see section 5.1).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults:_
_Schizophrenia:_ the recommended starting dose for Alcartis is 10 or
15 mg/day with a maintenance dose of 15 mg/day
administered on a once-a-day schedule without regard to meals.
Alcartis is effective in a dose range of 10 to 30 mg/day. Enhanced
efficacy at doses higher than a daily dose of 15 mg
has not been demonstrated although individual patients may benefit
from a higher dose. The maximum daily dose
should not exceed 30 mg.
_Manic episodes in Bipolar I Disorder:_ the recommended starting dose
for Alcartis is 15 mg administered on a once-a-
day schedule without regard to meals as monotherapy or combination
therapy (see section 5.1). Some patients may
benefit from a higher dose. The maximum daily dose should not exceed
30 mg.
_Recurrence prevention of manic episodes in Bipolar I Disorder:_ for
preventing recurrence of manic episodes in patients
who have been receiving aripiprazole as monotherapy or combination
therapy, continue therapy at 
                                
                                Lees het volledige document
                                
                            

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten